NXL vs. BSGM, NRXS, QTI, STRR, NUWE, HSDT, NDRA, TIVC, VRAYQ, and VIVE
Should you be buying Nexalin Technology stock or one of its competitors? The main competitors of Nexalin Technology include BioSig Technologies (BSGM), NeurAxis (NRXS), QT Imaging (QTI), Star Equity (STRR), Nuwellis (NUWE), Helius Medical Technologies (HSDT), ENDRA Life Sciences (NDRA), Tivic Health Systems (TIVC), ViewRay (VRAYQ), and Viveve Medical (VIVE). These companies are all part of the "electromedical equipment" industry.
BioSig Technologies (NASDAQ:BSGM) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
7.2% of BioSig Technologies shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 9.3% of BioSig Technologies shares are held by insiders. Comparatively, 27.7% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, BioSig Technologies and BioSig Technologies both had 3 articles in the media. BioSig Technologies' average media sentiment score of 1.89 beat Nexalin Technology's score of 1.59 indicating that Nexalin Technology is being referred to more favorably in the news media.
BioSig Technologies received 102 more outperform votes than Nexalin Technology when rated by MarketBeat users.
Nexalin Technology has higher revenue and earnings than BioSig Technologies.
BioSig Technologies has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 5.8, suggesting that its stock price is 480% more volatile than the S&P 500.
BioSig Technologies has a net margin of 0.00% compared to BioSig Technologies' net margin of -3,106.71%. BioSig Technologies' return on equity of -154.87% beat Nexalin Technology's return on equity.
Summary
Nexalin Technology beats BioSig Technologies on 7 of the 11 factors compared between the two stocks.
Get Nexalin Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nexalin Technology Competitors List
Related Companies and Tools
